

SEC USE ONLY
Prefix Serial
DATE RECEIVED

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

ORIGINAL

OMB APPROVAL
OMB Number: 3235-0076

Expires: May 31, 2002

Estimated average burden hours per response... 1

Name of Offering ({}) check if this is NOVADEL PHARMA INC.	s an amendment and name has changed, and ind	icate change.)	
Filing Under (Check box(es) that apply):	{ } Rule 504 { } Rule 505 {X} Rule 506 { }	Section 4(6) { } ULOE	04005508
Type of Filing: {X} New Filing { } A	nendment		
	A. BASIC IDENTIFICATI	ON DATA	
1. Enter the information requested about	the issuer		
Name of Issuer { } check if this is an a NOVADEL PHARMA INC.	mendment and name has changed, and indicate	change.	
Address of Executive Offices (Number a	nd Street, City, State, Zip Code)	Telephone Number (Includ	ing Area Code)
25 Minneakoning Road		(908) 782-3431	
Flemington, New Jersey 08822			
	(Number and Street, City, State, Zip Code)	Telephone Number (Includ	ling Area Code)
(if different from Executive Offices)		L	
Brief Description of Business			- OPF
Development stage pharmaceutical comp	any		POCESSED
Type of Business Organization			DROCE -
{X} corporation	{ } limited partnership, already formed	{ } other (please specify)	2 000k
{ } business trust	{ } limited partnership, to be formed		JAN 2 0 2004
	Month Year		
Actual or Estimated Date of Incorporation	. , , ,	X) Actual { } Estimated	THOMSON FINANCIAL
,	tion: (Enter two-letter U.S. Postal Service abbre		y 00

General Instructions

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer:
 - Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
 - Each general and managing partner of partnership issuers.

5	0.				
Check Box(es) that Apply: [] I	Promoter	[] Beneficial Owner	[X] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind	lividual)				
Shangold, Gary A., M.D.					
Business or Residence Address 25 Minneakoning Road, Flem			Code)		
Check Box(es) that Apply: [] l	Promoter	[X] Beneficial Owner	[X] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Dugger, III, Harry A., Ph.D.	lividual)				
Business or Residence Address 25 Minneakoning Road, Flem			Code)		
Check Box(es) that Apply: [] !		[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if ind Klein, John H.	lividual)				
Business or Residence Address 25 Minneakoning Road, Flem			Code)		
Check Box(es) that Apply: []]		[] Beneficial Owner	[X] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if inc Schaul, Robert F., Esq.					
Business or Residence Address 25 Minneakoning Road, Flem	ington, New .	Jersey 08822	Code)		
Check Box(es) that Apply: []		[] Beneficial Owner	[X] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, if inc Deitman, Donald J.					
Business or Residence Address 25 Minneakoning Road, Flem	ington, New .	Jersey 08822			
Check Box(es) that Apply: []	Promoter	[] Beneficial Owner	[X] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, if inc Abd El-Shafy, Mohammed, Ph.D),				
Business or Residence Address 25 Minneakoning Road, Flem	ington, New .	Jersey 08822			
Check Box(es) that Apply: []		[] Beneficial Owner	[X] Executive Officer	[] Director	[] General and/or Managing Partner
Full Name (Last name first, if inc Cohen, Barry					
Business or Residence Address 25 Minneakoning Road, Flem					****
Check Box(es) that Apply: []		[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner
Full Name (Last name first, if inc Hamilton, William F., Ph.D.					
Business or Residence Address 25 Minneakoning Road, Flem	•		Code)		

Check Box(es) that Apply: [] Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or Managing Partner	
Full Name (Last name first, if individual)				Transping Faither	
Kessel, Lawrence J., M.D., FACP				ž	
Business or Residence Address (Number a	nd Street City State Zin	Code)		<u> </u>	
25 Minneakoning Road, Flemington, New		C040)			
Check Box(es) that Apply: [] Promoter	[] Beneficial Owner	[] Executive Officer	[X] Director	General and/or	
Check Box(cs) that Apply. [] I follote	[] Belieficial Owlief	[] Executive Officer	[A] Director	Managing Partner	
Full Name (Last name first, if individual)		MP4		Trianaging 1 articl	
Rachesky, Mark H., M.D.					
Business or Residence Address (Number a	nd Street City State Zin	Code)			
25 Minneakoning Road, Flemington, New		C0 00)			
Check Box(es) that Apply: [] Promoter	Beneficial Owner	[] Executive Officer	[X] Director	[] General and/or	
enten zen(es) mar reprij. [] i temeter	[] Demondra o mile.	[] Direction of Chinese	[Al] Shoto.	Managing Partner	
Full Name (Last name first, if individual)					
Nemeroff, Charles, M.D., Ph.D.					
Business or Residence Address (Number a	nd Street, City, State, Zip	Code)			
25 Minneakoning Road, Flemington, Nev		,			
Check Box(es) that Apply: [] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or	
, , , , , , , , , , , , , , , , , , , ,				Managing Partner	
Full Name (Last name first, if individual)					
Rosenwald, Lindsay A., M.D.					
Business or Residence Address (Number a	nd Street, City, State, Zip	Code)			
787 Seventh Avenue, 48th Floor, New Yo			_		
Check Box(es) that Apply: [] Promoter	[X] Beneficial Owner	[] Executive Officer	[] Director	[] General and/or	
				Managing Partner	
Full Name (Last name first, if individual)					
Biomedical Investment Group, LLC					
Business or Residence Address (Number a		Code)			
787 Seventh Avenue, 48th Floor, New Yo	ork, NY 10019				

.

F 3, 1 %			3.3	3. INFO	RMATI(ON ABO	UT OFF	ERING		14:		
1. Has	s the issu	er sold, c					on-accred 2, if filir			is offering	g? Ye.	
2. Wha	t is the n	ninimum	investme	nt that w	ill be acc	epted fro	m any inc	dividual?			\$10	00,000
3. Does	the offe	ring pern	nit joint c	wnership	of a sing	gle unit?					Ye [X	
indir with a bro or de deale	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only. Full Name (Last name first, if individual) Paramount Capital, Inc.										.1 [1	
Busines	Business or Residence Address (Number and Street, City, State, Zip Code) 787 Seventh Avenue, 48th Floor New York, NY 10019											
Name o	f Associ	ated Brol	ker or De	aler								
States in	n Which	Person L	isted Has	Solicite	d or Inter	ids to Sol	licit Purcl	nasers			į	
(Check	"All Stat	tes" or ch	eck indiv	idual Sta	ites)							All States
[AL] [MT] [RI] Full Na	[AK] [IN] [NE] [SC] me (Last	[AZ] [IA] [NV] [SD] name fire	[AR] [KS] [NH] [TN] est, if indi	[CA] [KY] [N] [EX] vidual)	[CO] [LA] [NM] [UI]	[ME] [MY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[MI] [MI] [OH] [WV]	[MN] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]
Busines	s or Res	idence A	ddress (N	umber aı	nd Street,	City, Sta	ate, Zip C	ode)				
Name o	f Associ	ated Brol	ker or De	aler								
							licit Purcl					All States
[AL] [IL] [MT] [RI] Full Na	[AK] [IN] [NE] [SC] me (Last	[AZ] [IA] [NV] [SD] name fire	[AR] [KS] [NH] [TN] rst, if ind	[CA] [KY] [NJ] [TX] ividual)	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]
Busines	s or Res	idence A	ddress (N	lumber a	nd Street,	City, Sta	ate, Zip C	Code)		***	. She	
Name o	of Associ	ated Brol	ker or De	aler							•	
							licit Purc					All States
[AL] [IL] [MT] [RI]	[AK] [IN] [NE] [SC]	[AZ] [IA] [NV] [SD]	[AR] [KS] [NH] [TN]	[CA] [KY] [NJ] [TX]	[CO] [LA] [NM] [UT]	[CT] [ME] [NY] [VT]	[DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FL] [MI] [OH] [WV]	[GA] [MN] [OK] [WI]	[HI] [MS] [OR] [WY]	[ID] [MO] [PA] [PR]

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSE A	ND USE OF PRO	CEEDS
1.	Enter the aggregate offering price of securities included in this offering		
	and the total amount already sold. Enter "0" if answer is "none" or "zero."	\	
	If the transaction is an exchange offering, check this box \square and indicate in the columns below the amounts of the securities offered for exchange and	•	
	already exchanged.		
	Type of Security	Aggregate	Amount
		Offering Price	Already Sold
	Debt	\$	\$0
	Equity Common Preferred	\$	\$ <u>14,000,000</u>
	Convertible Securities (including warrants)	\$ <u></u>	\$
	Partnership Interests	\$	\$
	Other	\$ <u></u>	\$ <u></u>
	Total	\$	\$ <u>14,000,000</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have		
	purchased securities in this offering and the aggregate dollar amounts of		
	their purchases. For offerings under Rule 504, indicate the number of		
	persons who have purchased securities and the aggregate dollar amount of		
	their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of	: Aggregate
		Investors	Dollar Amount
			of Purchases
	Accredited Investors	0	\$
	Non-Accredited Investors	0 0	\$ <u></u> \$
	Total (for filings under Rule 504 only)		Ф ======
	•		
3.	If this filing is for an offering under Rule 504 or 505, enter the information		
	requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of		
	securities in this offering. Classify securities by type listed in		
	Part C - Question 1.		
		Type of	Dollar Amount
	Type of Offering	Security	Sold
	Rule 505	0	
	Rule 504	0	\$0
	Total	0	\$
4.	a. Furnish a statement of all expenses in connection with the issuance and		
	distribution of the securities in this offering. Exclude amounts relating		
	solely to organizational expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure	144	Sie
	is not known, furnish an estimate and check the box to the left of the		
	estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs		\$
	Legal Fees		\$0000
	Accounting Fees Engineering Fees	[] []	\$ <u></u> \$
	Sales Commissions (specify finders' fees separately)	[]	\$0
	carrie commissions (specify images toos separatory)	l j	<u> </u>

[X] \$ [X] \$

Other Expenses (identify). Placement agent fee.

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPE	NSES AND USE OF	PROCEEDS
b. Enter the difference between the aggregate offering price given in response to Part C – Question 1 and total expenses furnished in response to Part C – Question 4.a. This difference is the "adjusted gross proceeds to the issuer."		\$ <u>13,175,000</u>
5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b. above.		
	Payments to Officers, Directors, & Affiliates	Payments to Others
Salaries and fees	[] \$0 [] \$0	[] \$ <u>0</u>
Purchase, rental or leasing and installation of machinery and Equipment	[] \$0	[] \$0
Construction or leasing of plant buildings and facilities	[] \$	[] \$0
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	[] \$0	[] \$0 [] \$0
Other (specify): Research and Development	[] \$0	[X] \$ <u>3,293,750</u> [X] \$ <u>9,881,250</u>
Column Totals	[] \$0	[X] \$ <u>13,175,00</u>
Total Payments Listed (column totals added)	[X] \$ <u>13</u>	,175,000

· ·

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type)	Signature	Date
NOVADEL PHARMA INC.	Bank Shan	January 12, 2004
Name of Signer (Print or Type)	Title of Signer (Print or	Type)
Gary A. Shangold, M.D.	President and Chief Exec	autive Officer

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001)

E. STATE SIGNATURE
1. Is any party described in 17 CFR 230.252(c), (d), (e) or (f) presently subject to any of the disqualification Yes No provisions of such rule?
See Appendix, Column 5, for state response

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type)	Signature	Date
NOVADEL PHARMA INC.	Sand Shoneld	January 1 2 , 2004
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
Gary A. Shangold, M.D.	President and Chief Executive C	Officer

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1	2 3				5					
	Intend to non-ac investors (Part B-	credited in State	Type of security and aggregate offering price offered in state (Part C-Item 1)		Type of investor and amount purchased in State (Part C-Item 2)			Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No	
AL	103	1		Investors	Amount	Hivestors	ranount	103	110	
AK										
AZ		X					-		-	
AR				<u> </u>			I			
CA		X								
CO										
CT		X								
DE		X		· · · · · · · · · · · · · · · · · · ·						
DC		X								
FL		X								
GA		X								
HI										
ID										
IL		X								
IN										
IA										
KS		-								
KY		-								
LA						'				
ME										
MD						<u> </u>				
MA		X								
MI										
MN		X					196			
MS										
MO										

•						Annua Valencia		49°.	_
				APP	ENDIX	â'			
1	Intend to non-ac investors (Part B-	to sell credited in State	Type of security and aggregate offering price offered in state (Part C-Item 1)		4			5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors Amount		Number of Non-Accredited Investors	Yes	No	
MT									
NE									
NV		ļ <u>.</u>							
NH									
NJ		X							
NM									
NY		X							
NC									
ND									
ОН									
OK									
OR		X							
PA		X							
RI		X		_					
SC									
SD									
TN									
TX		X							
UT		X							
VT									
VA		X							
WA									
WV									
WI									
WY							· Sa.		
PR									